232 related articles for article (PubMed ID: 29915289)
41. Enhanced F508del-CFTR channel activity ameliorates bone pathology in murine cystic fibrosis.
Le Henaff C; Haÿ E; Velard F; Marty C; Tabary O; Marie PJ; Jacquot JP
Am J Pathol; 2014 Apr; 184(4):1132-1141. PubMed ID: 24529904
[TBL] [Abstract][Full Text] [Related]
42. Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia.
Tomati V; Caci E; Ferrera L; Pesce E; Sondo E; Cholon DM; Quinney NL; Boyles SE; Armirotti A; Ravazzolo R; Galietta LJ; Gentzsch M; Pedemonte N
JCI Insight; 2018 Feb; 3(3):. PubMed ID: 29415893
[TBL] [Abstract][Full Text] [Related]
43. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
44. Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes.
Mésinèle J; Ruffin M; Guillot L; Corvol H
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430680
[TBL] [Abstract][Full Text] [Related]
45. Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.
Cai Z; Palmai-Pallag T; Khuituan P; Mutolo MJ; Boinot C; Liu B; Scott-Ward TS; Callebaut I; Harris A; Sheppard DN
J Physiol; 2015 Jun; 593(11):2427-46. PubMed ID: 25763566
[TBL] [Abstract][Full Text] [Related]
46. Potentiation of the cystic fibrosis transmembrane conductance regulator Cl
Wang Y; Cai Z; Gosling M; Sheppard DN
Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L846-L857. PubMed ID: 30136610
[TBL] [Abstract][Full Text] [Related]
47. Defective CFTR promotes intestinal proliferation via inhibition of the hedgehog pathway during cystic fibrosis.
Liu K; Wang X; Zou C; Zhang J; Chen H; Tsang L; Yu MK; Chung YW; Wang J; Dai Y; Liu Y; Zhang X
Cancer Lett; 2019 Apr; 446():15-24. PubMed ID: 30639531
[TBL] [Abstract][Full Text] [Related]
48. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations.
Pedemonte N; Diena T; Caci E; Nieddu E; Mazzei M; Ravazzolo R; Zegarra-Moran O; Galietta LJ
Mol Pharmacol; 2005 Dec; 68(6):1736-46. PubMed ID: 16150931
[TBL] [Abstract][Full Text] [Related]
49. Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis.
Ahmadi S; Wu YS; Li M; Ip W; Lloyd-Kuzik A; Di Paola M; Du K; Xia S; Lew A; Bozoky Z; Forman-Kay J; Bear CE; Gonska T
Am J Respir Cell Mol Biol; 2019 Dec; 61(6):755-764. PubMed ID: 31189070
[TBL] [Abstract][Full Text] [Related]
50. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease.
Persu A; Devuyst O; Lannoy N; Materne R; Brosnahan G; Gabow PA; Pirson Y; Verellen-Dumoulin C
J Am Soc Nephrol; 2000 Dec; 11(12):2285-2296. PubMed ID: 11095651
[TBL] [Abstract][Full Text] [Related]
51. Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses.
Mueller C; Braag SA; Keeler A; Hodges C; Drumm M; Flotte TR
Am J Respir Cell Mol Biol; 2011 Jun; 44(6):922-9. PubMed ID: 20724552
[TBL] [Abstract][Full Text] [Related]
52. Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients.
Bensalem N; Ventura AP; Vallée B; Lipecka J; Tondelier D; Davezac N; Dos Santos A; Perretti M; Fajac A; Sermet-Gaudelus I; Renouil M; Lesure JF; Halgand F; Laprévote O; Edelman A
Mol Cell Proteomics; 2005 Oct; 4(10):1591-601. PubMed ID: 16014420
[TBL] [Abstract][Full Text] [Related]
53. [Relation between gene mutations and pancreatic exocrine function in patients with cystic fibrosis].
Radivojević D; Guć-Sćekić M; Djurisić M; Lalić T; Minić P; Kanavakis E
Srp Arh Celok Lek; 2001; 129 Suppl 1():6-9. PubMed ID: 15637983
[TBL] [Abstract][Full Text] [Related]
54. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities.
Li W; Soave D; Miller MR; Keenan K; Lin F; Gong J; Chiang T; Stephenson AL; Durie P; Rommens J; Sun L; Strug LJ
Hum Genet; 2014 Feb; 133(2):151-61. PubMed ID: 24057835
[TBL] [Abstract][Full Text] [Related]
55. Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes.
Salvatore F; Scudiero O; Castaldo G
Am J Med Genet; 2002 Jul; 111(1):88-95. PubMed ID: 12124743
[TBL] [Abstract][Full Text] [Related]
56. Fecal dysbiosis and inflammation in intestinal-specific Cftr knockout mice on regimens preventing intestinal obstruction.
Young SM; Woode RA; Williams EC; Ericsson AC; Clarke LL
Physiol Genomics; 2024 Mar; 56(3):247-264. PubMed ID: 38073491
[TBL] [Abstract][Full Text] [Related]
57. Modifier gene studies to identify new therapeutic targets in cystic fibrosis.
Dorfman R
Curr Pharm Des; 2012; 18(5):674-82. PubMed ID: 22229572
[TBL] [Abstract][Full Text] [Related]
58. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene.
Du M; Jones JR; Lanier J; Keeling KM; Lindsey JR; Tousson A; Bebök Z; Whitsett JA; Dey CR; Colledge WH; Evans MJ; Sorscher EJ; Bedwell DM
J Mol Med (Berl); 2002 Sep; 80(9):595-604. PubMed ID: 12226741
[TBL] [Abstract][Full Text] [Related]
59. Osteoclastogenesis and sphingosine-1-phosphate secretion from human osteoclast precursor monocytes are modulated by the cystic fibrosis transmembrane conductance regulator.
Jourdain ML; Sergheraert J; Braux J; Guillaume C; Gangloff SC; Hubert D; Velard F; Jacquot J
Biochim Biophys Acta Mol Basis Dis; 2021 Mar; 1867(3):166010. PubMed ID: 33188942
[TBL] [Abstract][Full Text] [Related]
60. [Cystic fibrosis modifying genes].
Knauer N; Ratjen F; Grasemann H
Pneumologie; 2005 Jun; 59(6):395-404. PubMed ID: 15991075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
